[Infostock Daily=Reporter Park Jeong-Do] GC Green Cross, which has been preparing Phase 2 clinical trials for the novel coronavirus (Covid-19) plasma treatment last month, has begun administering drugs to patients.
According to the pharmaceutical industry on March 21, GC Green Cross administered drugs to the first patient who participated in Phase 2 clinical trials of plasma treatment. It was only a month after the Food and Drug Administration approved Phase 2 clinical trials of the Covid-19 plasma treatment GC5131 from the Food and Drug Administration on the 20th of last month.
Phase 2 clinical trials will be conducted at six hospitals including Chungang University Hospital, Samsung Seoul Hospital, Seoul Asan Hospital, Ancient Ansan Hospital, Chungnam National University Hospital, and Severance Hospital. 60 patients with high-risk corona 19 patients with pneumonia or aged and underlying diseases are eligible.
Overseas, the company plans to enter Phase 3 clinical trials this month through the "CoVIg-19 Plasma Alliance for the Development of Covid-19 Plasma Therapy" (GC Green Cross) which participated. In addition to GC Green Cross, global blood products such as BPL, CSL, Takeda, Biotest, and Octa Pharma are participating in the Alliance for the Development of Covid-19 Plasma Therapy.
In Korea, only Phase 1 clinical trials were exempted, but Phase 1 and Phase 2 clinical trials were exempted overseas. Phase 3 clinical trials are led by the National Institutes of Allergy and Infectious Diseases (NIAID) under the National Institutes of Health (NIH), and will be administered to about 500 Corona 19 patients in the United States, Argentina, Denmark and the United Kingdom.
Reporter Park Jeong-Do newface0301@naver.com
